Evidence map›Paper›PMID 35539622›Full record

ArticleRSC advances2018

An efficient route to

Aoi Tazawa, Junki Ando, Kohei Ishizawa, Isao Azumaya, Hidemasa Hikawa, Minoru Tanaka

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 3 countries.

Aoi TazawaSohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation 1000 Kamoshida-cho, Aoba-ku Yokohama-shi Kanagawa 227-0033 Japan tanaka.minoru@mw.mt-pharma.co.jp.
Junki AndoSohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation 1000 Kamoshida-cho, Aoba-ku Yokohama-shi Kanagawa 227-0033 Japan tanaka.minoru@mw.mt-pharma.co.jp.
Kohei IshizawaSohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation 1000 Kamoshida-cho, Aoba-ku Yokohama-shi Kanagawa 227-0033 Japan tanaka.minoru@mw.mt-pharma.co.jp.
Isao AzumayaFaculty of Pharmaceutical Sciences, Toho University 2-2-1 Miyama Funabashi Chiba 274-8510 Japan isao.azumaya@phar.toho-u.ac.jp.ORCID https://orcid.org/0000-0002-6651-2768
Hidemasa HikawaFaculty of Pharmaceutical Sciences, Toho University 2-2-1 Miyama Funabashi Chiba 274-8510 Japan isao.azumaya@phar.toho-u.ac.jp.ORCID https://orcid.org/0000-0002-7819-3012
Minoru TanakaSohyaku Innovative Research Division, Mitsubishi Tanabe Pharma Corporation 1000 Kamoshida-cho, Aoba-ku Yokohama-shi Kanagawa 227-0033 Japan tanaka.minoru@mw.mt-pharma.co.jp.
International Innovative University · RUToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A facile synthetic procedure for the production of

Identifiers

PMID35539622
PMCPMC9078240
OpenAlexW2786991524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.